Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.68 USD | -1.98% | +0.25% | -31.76% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |